The coronavirus pandemic has highlighted the effectiveness of large, multisite clinical trials run under master protocols, especially when it comes to evaluating multiple experimental treatment options simultaneously. Despite their advantages, there are some challenges and costs associated with running master protocol trials that the industry is still grappling with.